Valine metabolites analysis in ECHS1 deficiency

Area of Science:

• Biochemistry
• Metabolomics
• Clinical Genetics

Background:

• Short-chain enoyl-CoA hydratase (ECHS1) deficiency impacts mitochondrial amino acid and fatty acid metabolism.
• This deficiency is linked to severe neurological disorders like Leigh syndrome and exercise-induced dystonia.
• Accumulation of valine metabolites is hypothesized to cause cytotoxicity.

Purpose of the Study:

• To identify reliable biomarkers for early diagnosis of ECHS1 deficiency.
• To evaluate the utility of specific urine metabolites in diagnosing ECHS1 deficiency.
• To assess the potential of these metabolites for monitoring dietary interventions.

Main Methods:

• Liquid chromatography with tandem mass spectrometry (LC-MS/MS) was employed for metabolite analysis.
• Urine and plasma samples from six ECHS1 deficiency patients (four new cases) and six healthy controls were analyzed.
• Quantification of specific cysteine/cysteamine conjugates derived from valine metabolites was performed.

Main Results:

• Distinct patterns of urine cysteine/cysteamine conjugates were observed between patients and controls.
• Elevated levels of S-(2-carboxypropyl) cysteine/cysteamine and S-(2-carboxyethyl) cysteine/cysteamine were detected in patients.
• These specific metabolites showed potential for differentiating ECHS1 deficiency.

Conclusions:

• LC-MS/MS analysis of specific urine metabolites offers a promising approach for early diagnosis of ECHS1 deficiency.
• Identified metabolites can aid in evaluating the efficacy of protein-restricted diet therapy.
• Early diagnosis and management are essential for improving neurological outcomes in ECHS1 deficiency.